Skip to main content
Premium Trial:

Request an Annual Quote

Compugen s Q1 Revenues Slide 43 Percent as R&D, Losses Swell

NEW YORK, April 20 (GenomeWeb News) - Compugen today reported an 43-percent drop in revenues and a rising net loss for the first quarter of 2005.


Revenues for the quarter ended March 31 fell to $865,000 from $1.52 million during the same period last year. Around $384,000 of those receipts came from government and other grants.


R&D expenses increased to $3.5 million from $2.9 million during the same quarter in 2004.


The company's net loss for the quarter increased to $3.74 million, or $.13 per share, from $3 million, or $.11 per share, for the same quarter last year.


As of March 31, Compugen had $43.5 million in cash, cash equivalents, and marketable securities, of which $23.78 million are long-term marketable securities.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.